Literature DB >> 34495021

How we treat mycosis fungoides and Sézary syndrome.

Niloufer Khan1, Sarah J Noor2, Steven Horwitz1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34495021      PMCID： PMC9364355     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  46 in total

1.  Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.

Authors:  Melissa Pulitzer; Patricia L Myskowski; Steven M Horwitz; Christiane Querfeld; Brian Connolly; Janet Li; Rajmohan Murali
Journal:  Pathology       Date:  2014-12       Impact factor: 5.306

2.  Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.

Authors:  Debra Breneman; Madeleine Duvic; Timothy Kuzel; Richard Yocum; Joseph Truglia; Victor J Stevens
Journal:  Arch Dermatol       Date:  2002-03

3.  The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group.

Authors:  Stephen Morris; Julia Scarisbrick; John Frew; Clive Irwin; Robert Grieve; Caroline Humber; Aleksandra Kuciejewska; Sally Bayne; Sophie Weatherhead; Fiona Child; Mary Wain; Sean Whittaker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-06-09       Impact factor: 7.038

4.  Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.

Authors:  Enrica Marchi; Lapo Alinari; Monica Tani; Vittorio Stefoni; Nicola Pimpinelli; Emilio Berti; Livio Pagano; Maria Grazia Bernengo; Francesco Zaja; Serena Rupoli; Stefano Pileri; Michele Baccarani; Pier Luigi Zinzani
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

5.  Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

Authors:  M Duvic; K Hymes; P Heald; D Breneman; A G Martin; P Myskowski; C Crowley; R C Yocum
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

6.  Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma.

Authors:  Abigail Wright; Aruni Wijeratne; Tracy Hung; Wei Gao; Sean Whittaker; Steven Morris; Julia Scarisbrick; Teresa Beynon
Journal:  J Pain Symptom Manage       Date:  2012-08-20       Impact factor: 3.612

7.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Authors:  Richard L Piekarz; Robin Frye; Maria Turner; John J Wright; Steven L Allen; Mark H Kirschbaum; Jasmine Zain; H Miles Prince; John P Leonard; Larisa J Geskin; Craig Reeder; David Joske; William D Figg; Erin R Gardner; Seth M Steinberg; Elaine S Jaffe; Maryalice Stetler-Stevenson; Stephen Lade; A Tito Fojo; Susan E Bates
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

8.  Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

Authors:  Alexander M Lesokhin; Stephen M Ansell; Philippe Armand; Emma C Scott; Ahmad Halwani; Martin Gutierrez; Michael M Millenson; Adam D Cohen; Stephen J Schuster; Daniel Lebovic; Madhav Dhodapkar; David Avigan; Bjoern Chapuy; Azra H Ligon; Gordon J Freeman; Scott J Rodig; Deepika Cattry; Lili Zhu; Joseph F Grosso; M Brigid Bradley Garelik; Margaret A Shipp; Ivan Borrello; John Timmerman
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

9.  Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome.

Authors:  Gaëlle Quereux; Sonia Marques; Jean-Michel Nguyen; Christophe Bedane; Michel D'incan; Olivier Dereure; Elisabeth Puzenat; Alain Claudy; Ludovic Martin; Pascal Joly; Michele Delaunay; Marie Beylot-Barry; Pierre Vabres; Philippe Celerier; Bruno Sasolas; Florent Grange; Amir Khammari; Brigitte Dreno
Journal:  Arch Dermatol       Date:  2008-06

10.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Authors:  Youn H Kim; Martine Bagot; Lauren Pinter-Brown; Alain H Rook; Pierluigi Porcu; Steven M Horwitz; Sean Whittaker; Yoshiki Tokura; Maarten Vermeer; Pier Luigi Zinzani; Lubomir Sokol; Stephen Morris; Ellen J Kim; Pablo L Ortiz-Romero; Herbert Eradat; Julia Scarisbrick; Athanasios Tsianakas; Craig Elmets; Stephane Dalle; David C Fisher; Ahmad Halwani; Brian Poligone; John Greer; Maria Teresa Fierro; Amit Khot; Alison J Moskowitz; Amy Musiek; Andrei Shustov; Barbara Pro; Larisa J Geskin; Karen Dwyer; Junji Moriya; Mollie Leoni; Jeffrey S Humphrey; Stacie Hudgens; Dmitri O Grebennik; Kensei Tobinai; Madeleine Duvic
Journal:  Lancet Oncol       Date:  2018-08-09       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.